| 2025-12-04 |
详情>>
内部人交易：
Jimenez Freddy A.股份减少4166.00股
|
| 2025-11-10 |
详情>>
股本变动：
变动后总股本6644.95万股
|
| 2025-11-10 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-2.67美元,归母净利润-1.77亿美元,同比去年增长-60.19%
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益-1.66美元,归母净利润-1.1亿美元,同比去年增长-60.81%
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-0.81美元,归母净利润-5379.6万美元,同比去年增长-63.97%
|
| 2025-04-21 |
股东大会：
将于2025-06-05召开股东大会
会议内容 ▼▲
- 1.Elect nine directors to serve until the next Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified;
2.Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2025;
3.Approve an amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of the shares reserved for issuance thereunder by 2,000,000 shares to 9,500,000 shares;
4.Approve, on an advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in this proxy statement;
|
| 2025-02-27 |
详情>>
业绩披露：
2022年年报每股收益-2.4美元,归母净利润-1.12亿美元,同比去年增长-59.3%
|
| 2025-02-27 |
详情>>
业绩披露：
2024年年报每股收益-2.45美元,归母净利润-1.58亿美元,同比去年增长-11.62%
|
| 2024-11-06 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.74美元,归母净利润-1.11亿美元,同比去年增长-12.89%
|
| 2024-09-25 |
复牌提示：
2024-09-25 11:01:11 停牌，复牌日期 2024-09-25 11:06:11
|
| 2024-08-08 |
详情>>
业绩披露：
2023年中报每股收益-1.27美元,归母净利润-5986.3万美元,同比去年增长-1.37%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-1.1美元,归母净利润-6865万美元,同比去年增长-14.68%
|
| 2024-05-06 |
详情>>
业绩披露：
2024年一季报每股收益-0.56美元,归母净利润-3280.8万美元,同比去年增长-11.74%
|
| 2024-04-25 |
股东大会：
将于2024-06-13召开股东大会
会议内容 ▼▲
- 1.Elect nine directors to serve until the next Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified.
2.Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2024.
3.Approve an amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of the shares reserved for issuance thereunder by 3,200,000 shares to 7,500,000 shares.
4.Approve, on an advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in this proxy statement.
5.Address any other matters that may properly come before the meeting.
|
| 2024-02-26 |
详情>>
业绩披露：
2023年年报每股收益-2.92美元,归母净利润-1.41亿美元,同比去年增长-25.91%
|
| 2023-11-02 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-2.08美元,归母净利润-9812.3万美元,同比去年增长-14.31%
|
| 2023-04-25 |
股东大会：
将于2023-06-15召开股东大会
会议内容 ▼▲
- 1.Elect nine directors to serve until the next Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified;
2.Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2023;
3.Approve an amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of the shares reserved for issuance thereunder by 600,000 shares to 4,300,000 shares;
4.Approve, on an advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in this proxy statement;
5.To vote, on an advisory basis, on how often we will conduct an advisory vote on the compensation of our Named Executive Officers (every year, every two years or every three years);
6.Address any other matters that may properly come before the meeting.
|
| 2022-04-26 |
股东大会：
将于2022-06-16召开股东大会
会议内容 ▼▲
- 1.elect eight directors to serve until the next Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified;
2.ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2022;
3.approve, on an advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in this proxy statement;
4.address any other matters that may properly come before the meeting.
|
| 2022-02-28 |
财报披露：
美东时间 2022-02-28 盘后发布财报
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-27 |
股东大会：
将于2021-06-17召开股东大会
会议内容 ▼▲
- 1.elect six directors to serve until the next Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified;
2.ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2021;
3.approve our 2021 Omnibus Equity Incentive Plan;
4.approve, on an advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in this proxy statement;
5.address any other matters that may properly come before the meeting.
|
| 2020-04-28 |
股东大会：
将于2020-06-18召开股东大会
会议内容 ▼▲
- 1.elect six directors to serve until the next Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified;
2.ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2020;
3.approve an amendment to our 2008 Stock Option and Incentive Plan including an increase in the number of the shares reserved for issuance thereunder by 1,900,000 shares to 4,133,333 shares and certain other administrative changes;
4.approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in this proxy statement;
5.address any other matters that may properly come before the meeting.
|
| 2019-04-26 |
股东大会：
将于2019-06-19召开股东大会
会议内容 ▼▲
- 1.elect six directors to serve until the next Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified;
2.ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2019;
3.approve an amendment to our 2008 Stock Option and Incentive Plan including an increase in the number of the shares reserved for issuance thereunder by 900,000 shares to 2,233,333 shares and certain other administrative changes;
4.approve an amendment to our 2004 Employee Stock Purchase Plan to increase the shares reserved for issuance thereunder by 250,000 shares to 276,666 shares;
5.approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in this proxy statement;
6.address any other matters that may properly come before the meeting.
|
| 2019-02-11 |
详情>>
拆分方案：
每15.0000合并分成1.0000股
|
| 2018-04-30 |
股东大会：
将于2018-06-13召开股东大会
会议内容 ▼▲
- 1.elect eight directors to serve until the next Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified;
2.ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2018;
3.approve an amendment to our Restated Certificate of Incorporation, as amended, and grant of discretionary authority to the Board of Directors to effect a reverse stock split;
4.approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in this proxy statement;
5.address any other matters that may properly come before the meeting.
|
| 2017-04-28 |
股东大会：
将于2017-06-15召开股东大会
会议内容 ▼▲
- 1.elect eight directors to serve until the next Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified;
2.ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2017;
3.approve, in accordance with the applicable rules of the NASDAQ Stock Market, the issuance of shares of our common stock in connection with Milestone Payments that may become payable in the future to former securityholders of Kolltan Pharmaceuticals, Inc. under the terms of the Merger Agreement we entered into in November 2016;
4.approve an amendment to our 2008 Stock Option and Incentive Plan to increase the shares reserved for issuance thereunder by 5,650,000 shares to 20,000,000 shares;
5.approve an amendment to our 2004 Employee Stock Purchase Plan to increase the shares reserved for issuance thereunder by 200,000 shares to 400,000 shares;
6.approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in this proxy statement;
7.indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's Named Executive Officers;
8.address any other matters that may properly come before the meeting.
|
| 2016-04-21 |
股东大会：
将于2016-06-08召开股东大会
会议内容 ▼▲
- 1.elect seven directors to serve until the next Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified;
2.ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2016;
3.approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in this proxy statement
4.address any other matters that may properly come before the meeting.
|